ALPS Advisors’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $615K | Sell |
43,969
-17,509
| -28% | -$245K | ﹤0.01% | 597 |
|
|
2025
Q1 | $829K | Sell |
61,478
-2,579
| -4% | -$34.8K | ﹤0.01% | 515 |
|
|
2024
Q4 | $1.23M | Buy |
64,057
+17,232
| +37% | +$330K | 0.01% | 438 |
|
|
2024
Q3 | $1.07M | Sell |
46,825
-2,941
| -6% | -$66.9K | 0.01% | 478 |
|
|
2024
Q2 | $647K | Buy |
49,766
+5,490
| +12% | +$71.4K | ﹤0.01% | 543 |
|
|
2024
Q1 | $775K | Buy |
44,276
+9,422
| +27% | +$165K | 0.01% | 541 |
|
|
2023
Q4 | $759K | Buy |
34,854
+2,592
| +8% | +$56.5K | 0.01% | 541 |
|
|
2023
Q3 | $495K | Buy |
32,262
+555
| +2% | +$8.51K | ﹤0.01% | 600 |
|
|
2023
Q2 | $754K | Buy |
+31,707
| New | +$754K | 0.01% | 543 |
|
|
2022
Q4 | – | Sell |
-20,848
| Closed | -$428K | – | 1091 |
|
|
2022
Q3 | $428K | Buy |
20,848
+4,288
| +26% | +$88K | ﹤0.01% | 640 |
|
|
2022
Q2 | $192K | Buy |
+16,560
| New | +$192K | ﹤0.01% | 1001 |
|